
Albireo Pharma Long-Term Debt | ALBO
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.8 M | 3.56 M | 4.19 M | - | - | - | 4.87 M | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.8 M | 3.56 M | 5.86 M |
Quarterly Long-Term Debt Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 10.8 M | - | - | - | 3.56 M | - | - | - | 4.19 M | 4.33 M | 200 K | 213 K | - | - | - | - | - | - | - | - | - | - | - | - | 4.87 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.8 M | 200 K | 4.02 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
25.4 M | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
2.39 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
205 K | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
80.6 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
328 K | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
8.21 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
2.07 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
23.3 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
410 K | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
5.19 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
2 K | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
44 K | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
11.2 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
262 K | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
303 K | - | - | $ 35.3 M | ||
|
Axcella Health
AXLA
|
25.1 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
13.3 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
125 M | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
7.04 M | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
326 K | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
120 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
60.3 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
3.81 K | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
673 K | - | - | $ 109 M | ||
|
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
11.1 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
263 K | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
310 K | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
31.2 M | - | - | $ 591 K | ||
|
Navidea Biopharmaceuticals
NAVB
|
1.31 K | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
13.7 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
937 K | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
219 K | - | -4.8 % | $ 255 M | ||
|
bluebird bio
BLUE
|
7.8 M | - | - | $ 546 M | ||
|
CASI Pharmaceuticals
CASI
|
476 K | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
2.21 M | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
12 M | - | - | $ 728 M |